Drug Affected
|
ATV
|
FPV
|
LPV/r
|
RTV
|
SQV
|
TPV
|
DRV |
Dose: ATV 300 mg once daily + DRV 600 mg BID + RTV 100 mg BID |
No data |
Should not be co-administered because doses are not established |
Dose: (DRV 600 mg + RTV 100 mg) BID or (DRV 800 mg + RTV 100 mg) once daily |
Should not be co-administered because doses are not established |
No data |
FPV |
Dose: Insufficient data |
•
|
Should not be co-administered because doses are not established |
Dose: (FPV 1400 mg + RTV 100 mg or 200 mg) once daily; or (FPV 700 mg + RTV 100 mg) BID |
Dose: Insufficient data |
Should not be co-administered because doses are not established |
LPV/r |
Dose: ATV 300 mg once daily + LPV/r 400/100 mg BID |
Should not be co-administered because doses are not established |
•
|
LPV is coformulated with RTV as Kaletra. |
Dose: SQV 1000 mg BID + LPV/r 400/100 mg BID |
Should not be co-administered because doses are not established |
RTV |
Dose: (ATV 300 mg + RTV 100 mg) once daily |
Dose: (FPV 1400 mg + RTV [100 mg or 200 mg]) once daily;
or
(FPV 700 mg + RTV 100 mg) BID |
LPV is coformulated with RTV and marketed as Kaletra. |
•
|
Dose: (SQV 1000 mg + RTV 100 mg) BID |
Dose: (TPV 500 mg + RTV 200 mg) BID |
SQV |
Dose: Insufficient data |
Dose: Insufficient data |
Dose: SQV 1000 mg BID + LPV/r 400/100 mg BID |
Dose: (SQV 1000 mg + RTV 100 mg) BID |
•
|
Should not be co-administered because doses are not established |